Literature DB >> 10359124

Impaired apoptotic deletion of myelin basic protein-reactive T cells in patients with multiple sclerosis.

Y C Zang1, M M Kozovska, J Hong, S Li, S Mann, J M Killian, V M Rivera, J Z Zhang.   

Abstract

T cell responses to myelin basic protein (MBP) may play an important role in the pathogenesis of multiple sclerosis (MS). If MBP-reactive T cells are involved in the disease processes and undergo clonal activation and expansion, their precursor frequency would be increased in patients with MS. The frequency of MBP-reactive T cells is also influenced by regulatory mechanisms in vivo, including apoptotic deletion. In this study, we examined changes in the frequency of MBP-reactive T cells in patients with MS as a function of the apoptotic deletional mechanism in vivo, using a cell culture-based assay. A significantly increased frequency of MBP-reactive T cells was found in patients with MS relative to healthy individuals only when Fas-ligand antibody was used to block apoptosis. This result indicates that a significant proportion of MBP-reactive T cells are sensitive to apoptosis and are not deleted in vivo in patients with MS, as opposed to healthy individuals, thus suggesting a functional deficit in apoptotic deletional mechanism. Surviving Fas-sensitive MBP-reactive T cell lines represent distinct subpopulations preferentially recognizing the 111-139 region of MBP and exhibiting a Th2 cytokine profile. The findings are relevant to our understanding of regulation of MBP-reactive T cells in vivo in MS.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10359124     DOI: 10.1002/(SICI)1521-4141(199905)29:05<1692::AID-IMMU1692>3.0.CO;2-H

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  11 in total

1.  Increased spontaneous ex vivo apoptosis and subset alterations in peripheral blood T cells from patients with multiple sclerosis.

Authors:  Alfredo Prieto; David Díaz; Hugo Barcenilla; Carmen Castrillo; Jorge Monserrat; Antonio García Merino; Melchor Alvarez-Mon
Journal:  J Clin Immunol       Date:  2006-05-02       Impact factor: 8.317

2.  Treatment with methylprednisolone in relapses of multiple sclerosis patients: immunological evidence of immediate and short-term but not long-lasting effects.

Authors:  E M Martínez-Cáceres; M A Barrau; L Brieva; C Espejo; N Barberà; X Montalban
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

3.  Differential responses of CD45+ve T-cell subsets to MBP in multiple sclerosis.

Authors:  M Ponsford; G Mazza; J Coad; M J Campbell; J Zajicek; D C Wraith
Journal:  Clin Exp Immunol       Date:  2001-05       Impact factor: 4.330

4.  Comparison of several techniques for the detection of apoptotic astrocytes in vitro.

Authors:  F Micoud; B Mandrand; C Malcus-Vocanson
Journal:  Cell Prolif       Date:  2001-04       Impact factor: 6.831

5.  Characterizing a soluble survival signal for activated lymphocytes from CD14+ cells.

Authors:  Xiaolei Tang; David E Yocum; David DeJonghe; Kathy Nordensson
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

6.  Atorvastatin does not alter serum levels of sCD95 and sCD95L in multiple sclerosis.

Authors:  J Sellner; I Greeve; O Findling; D Grandgirard; S L Leib; H P Mattle
Journal:  Clin Exp Immunol       Date:  2008-03-12       Impact factor: 4.330

7.  Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis.

Authors:  Mark S Freedman; Johanne M Kaplan; Silva Markovic-Plese
Journal:  J Clin Cell Immunol       Date:  2013-07-08

Review 8.  Theiler's virus infection: a model for multiple sclerosis.

Authors:  Emilia L Oleszak; J Robert Chang; Herman Friedman; Christos D Katsetos; Chris D Platsoucas
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

9.  Cross-sectional and longitudinal analysis of myelin-reactive T cells in patients with multiple sclerosis.

Authors:  Jan D Lünemann; Sandra Rückert; Florian Kern; Uwe Wendling; Ruud van der Zee; Hans D Volk; Frauke Zipp
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

10.  IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).

Authors:  Joanne L Jones; Chia-Ling Phuah; Amanda L Cox; Sara A Thompson; Maria Ban; Jacqueline Shawcross; Amie Walton; Stephen J Sawcer; Alastair Compston; Alasdair J Coles
Journal:  J Clin Invest       Date:  2009-06-22       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.